Intermolecular Stockholders Agree to Merck KGaA Acquisition
July 18 2019 - 4:40AM
Dow Jones News
By Anthony Shevlin
Merck KGaA (MRK.XE) said Thursday that Intermolecular Inc. (IMI)
stockholders have approved the acquisition by the German
company.
The transaction is expected to close in the second half, Merck
said.
The pharmaceutical company agreed to acquire Intermolecular in
May through a subsidiary for $1.20 per share in an all-cash
transaction, which represented an equity value of around $62
million.
Merck will acquire Intermolecular through its subsidiary EMD
Group Holding II, Inc.
Write to Anthony Shevlin at anthony.shevlin@dowjones.com;
@anthony_shevlin
(END) Dow Jones Newswires
July 18, 2019 04:25 ET (08:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Intermolecular (NASDAQ:IMI)
Historical Stock Chart
From Feb 2025 to Mar 2025
Intermolecular (NASDAQ:IMI)
Historical Stock Chart
From Mar 2024 to Mar 2025
